Regeneron’s Eylea still sitting pretty even after new data from would-be rivals Roche, Novartis: analyst

Regeneron’s executives don’t see a reason to worry about Eylea’s growth prospects. And after this weekend’s data presentations from potential competitors, some analysts agree.Original Article